Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $20.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its price target hoisted by Mizuho from $19.00 to $20.00 in a report released on Thursday,Benzinga reports. Mizuho currently has a neutral rating on the stock.

APLS has been the subject of several other research reports. Cantor Fitzgerald cut their target price on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a research note on Tuesday, January 13th. Needham & Company LLC decreased their price target on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Royal Bank Of Canada lowered their price target on shares of Apellis Pharmaceuticals from $22.00 to $21.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 25th. Wedbush cut their price objective on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Finally, HC Wainwright boosted their price objective on shares of Apellis Pharmaceuticals from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Twelve investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $32.72.

Apellis Pharmaceuticals Trading Down 0.4%

Shares of APLS stock opened at $20.07 on Thursday. The company’s fifty day simple moving average is $22.50 and its two-hundred day simple moving average is $23.55. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.14 and a quick ratio of 2.70. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $30.48. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of 154.40 and a beta of 0.26.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.86. The firm had revenue of $199.91 million during the quarter, compared to analyst estimates of $199.28 million. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The business’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same period last year, the company earned ($0.29) earnings per share. As a group, analysts anticipate that Apellis Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In other news, CEO Cedric Francois sold 27,192 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $591,969.84. Following the completion of the sale, the chief executive officer owned 286,045 shares in the company, valued at approximately $6,227,199.65. This trade represents a 8.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Jeffrey Delong sold 3,371 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $73,386.67. Following the transaction, the insider directly owned 78,353 shares of the company’s stock, valued at $1,705,744.81. The trade was a 4.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 120,537 shares of company stock worth $2,608,532. 6.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its holdings in shares of Apellis Pharmaceuticals by 0.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 58,856 shares of the company’s stock worth $1,019,000 after buying an additional 465 shares during the last quarter. Wedmont Private Capital lifted its holdings in shares of Apellis Pharmaceuticals by 4.1% during the 4th quarter. Wedmont Private Capital now owns 11,883 shares of the company’s stock worth $315,000 after acquiring an additional 468 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of Apellis Pharmaceuticals by 0.6% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 96,125 shares of the company’s stock worth $2,415,000 after acquiring an additional 530 shares during the last quarter. Amalgamated Bank grew its position in Apellis Pharmaceuticals by 6.9% in the third quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock worth $196,000 after acquiring an additional 563 shares in the last quarter. Finally, Xponance LLC grew its position in Apellis Pharmaceuticals by 3.9% in the fourth quarter. Xponance LLC now owns 18,164 shares of the company’s stock worth $456,000 after acquiring an additional 681 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.